134 related articles for article (PubMed ID: 17922361)
1. Functional characterization of CYP2A13 polymorphisms.
Schlicht KE; Michno N; Smith BD; Scott EE; Murphy SE
Xenobiotica; 2007 Dec; 37(12):1439-49. PubMed ID: 17922361
[TBL] [Abstract][Full Text] [Related]
2. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2A13 active site mutation N297A on metabolism of coumarin and tobacco-specific nitrosamines.
Schlicht KE; Berg JZ; Murphy SE
Drug Metab Dispos; 2009 Mar; 37(3):665-71. PubMed ID: 19074523
[TBL] [Abstract][Full Text] [Related]
4. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
5. An investigation of the catalytic activity of CYP2A13*4 with coumarin and polymorphisms of CYP2A13 in a Chinese Han population.
Liu T; Hong Y; Li Z; Hong J; Zeng S; Zheng M; Chen S
Drug Metab Dispos; 2012 May; 40(5):847-51. PubMed ID: 22315333
[TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
7. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation.
He XY; Shen J; Hu WY; Ding X; Lu AY; Hong JY
Arch Biochem Biophys; 2004 Jul; 427(2):143-53. PubMed ID: 15196988
[TBL] [Abstract][Full Text] [Related]
8. Evidence for metabolic activation of N'-nitrosonornicotine and N-nitrosobenzylmethylamine by a rat nasal coumarin hydroxylase.
Patten CJ; Peterson LA; Murphy SE
Drug Metab Dispos; 1998 Feb; 26(2):177-80. PubMed ID: 9456305
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation.
Kumondai M; Hosono H; Maekawa M; Yamaguchi H; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Feb; 33(1):82-89. PubMed ID: 29342418
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of nicotine and cotinine by human cytochrome P450 2A13.
Bao Z; He XY; Ding X; Prabhu S; Hong JY
Drug Metab Dispos; 2005 Feb; 33(2):258-61. PubMed ID: 15528319
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N'-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine.
Wong HL; Murphy SE; Hecht SS
Chem Res Toxicol; 2005 Jan; 18(1):61-9. PubMed ID: 15651850
[TBL] [Abstract][Full Text] [Related]
13. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
14. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
15. CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers.
Kumondai M; Hosono H; Orikasa K; Arai Y; Arai T; Sugimura H; Ozono S; Sugiyama T; Takayama T; Sasaki T; Hirasawa N; Hiratsuka M
Biol Pharm Bull; 2016; 39(10):1683-1686. PubMed ID: 27725446
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N'- nitrosonornicotine in human hepatic microsomes.
Staretz ME; Murphy SE; Patten CJ; Nunes MG; Koehl W; Amin S; Koenig LA; Guengerich FP; Hecht SS
Drug Metab Dispos; 1997 Feb; 25(2):154-62. PubMed ID: 9029045
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective metabolism of nicotine and tobacco-specific N-nitrosamines to 4-hydroxy-4-(3-pyridyl)butanoic acid in rats.
Trushin N; Hecht SS
Chem Res Toxicol; 1999 Feb; 12(2):164-71. PubMed ID: 10027794
[TBL] [Abstract][Full Text] [Related]
19. Effects of 8-methoxypsoralen on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.
Feng M; Zhang H; Cao B; Liu S; Mao J; Zhang Q
Drug Metab Pharmacokinet; 2015 Aug; 30(4):314-20. PubMed ID: 26210672
[TBL] [Abstract][Full Text] [Related]
20. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
